CHINA PHARMA HOLDINGS, INC. Repayments of Related Party Debt
CHINA PHARMA HOLDINGS, INC. (CPHI) reported Repayments of Related Party Debt of $223.01 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2024-04-01.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfRelatedPartyDebt · last filed 2024-04-01
- CHINA PHARMA HOLDINGS, INC. repayments of related party debt for the quarter ending 2022-12-31 was -$4.03K, a 101.30% decline year-over-year.
- CHINA PHARMA HOLDINGS, INC. repayments of related party debt for the quarter ending 2022-09-30 was -$4.32K, a 28880.00% decline year-over-year.
- CHINA PHARMA HOLDINGS, INC. repayments of related party debt for the quarter ending 2022-06-30 was -$4.85K, a 1089.80% decline year-over-year.
- CHINA PHARMA HOLDINGS, INC. repayments of related party debt for the quarter ending 2022-03-31 was $236.21K, a 6.03% decline year-over-year.
- CHINA PHARMA HOLDINGS, INC. repayments of related party debt for fiscal 2022 was $223.01K, a 60.36% decline from fiscal 2021.
- CHINA PHARMA HOLDINGS, INC. repayments of related party debt for fiscal 2021 was $562.66K, a 193.60% increase from fiscal 2020.
- CHINA PHARMA HOLDINGS, INC. repayments of related party debt for fiscal 2020 was $191.64K, a 22.04% decline from fiscal 2019.
- CHINA PHARMA HOLDINGS, INC. repayments of related party debt for fiscal 2019 was $245.83K.
| Period end | Repayments of Related Party Debt 3 month | Repayments of Related Party Debt 6 month | Repayments of Related Party Debt 9 month | Repayments of Related Party Debt 12 month |
|---|---|---|---|---|
| 2022-12-31 | -$4.03K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$8.34K derived: sum of 2 quarters · filed 2024-04-01 | -$13.19K derived: sum of 3 quarters · filed 2024-04-01 | $223.01K 10-K · filed 2024-04-01 |
| 2022-09-30 | -$4.32K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$9.17K derived: sum of 2 quarters · filed 2023-11-13 | $227.04K 10-Q · filed 2023-11-13 | $537.82K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$4.85K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $231.36K 10-Q · filed 2023-08-14 | $542.14K derived: sum of 3 quarters · filed 2023-08-14 | $542.15K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $236.21K 10-Q · filed 2023-05-12 | $546.99K derived: sum of 2 quarters · filed 2023-05-12 | $547.00K derived: sum of 3 quarters · filed 2023-05-12 | $547.49K derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $310.78K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $310.80K derived: sum of 2 quarters · filed 2023-03-30 | $311.29K derived: sum of 3 quarters · filed 2023-03-30 | $562.66K 10-K · filed 2023-03-30 |
| 2021-09-30 | $15.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $505.00 derived: sum of 2 quarters · filed 2022-11-14 | $251.88K 10-Q · filed 2022-11-14 | $365.99K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $490.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $251.86K 10-Q · filed 2022-08-11 | $365.97K derived: sum of 3 quarters · filed 2022-08-11 | |
| 2021-03-31 | $251.37K 10-Q · filed 2022-05-12 | $365.48K derived: sum of 2 quarters · filed 2022-05-12 | ||
| 2020-12-31 | $114.11K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $191.64K 10-K · filed 2022-03-30 | ||
| 2020-09-30 | $77.53K 10-Q · filed 2021-11-12 | |||
| 2019-12-31 | $245.83K 10-K · filed 2021-03-26 | |||
| 2019-06-30 | $111.69K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $231.25K 10-Q · filed 2019-08-14 | ||
| 2019-03-31 | $119.56K 10-Q · filed 2019-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |